Science news and discoveries from Mass General Brigham
Bench PressBench PressBench PressBench Press
  • Home
  • About Us
  • Research
    • Brain Research
    • Heart
    • Cancer
    • More…

Alzheimer’s Disease Expert Says Future Treatment Success Will Require a Shift in Strategy and Timing

By mghresearch | Alzheimer's Disease, Neurology | 2 comments | 3 October, 2019 | 0

What will the diagnosis and treatment of Alzheimer’s disease look like 35 years from now?

That was one of the compelling questions tackled during a panel discussion earlier this year at the Partners Innovation World Medical Innovation Forum.

The discussion was inspired by a series of predictions that the noted author Isaac Asimov made in 1984 about what life would be like 35 years later in 2019.

Using Genetics and Family History as a Guide

Rudy Tanzi, PhD, Director of the Genetics and Aging Research Unit at Massachusetts General Hospital, said future success in treating Alzheimer’s disease will come from earlier diagnosis and treatment guided by an individual’s family history and genetic risk factors.

“If you’re in a family with Alzheimer’s disease, look at the earliest age of onset in a first-degree relative. Subtract 20 years and that’s when you want to start looking for problems, because that’s when you want to start treating.”

In contrast to cancer, diabetes and heart disease—where early detection and treatment is key—treatments for Alzheimer’s disease don’t start until patients start showing symptoms of cognitive decline, Tanzi noted. By then, it may be too late to make a difference.

Strategies for Early Intervention

One key to early intervention is to identify imaging or blood tests that can detect the onset of the disease—the formation of amyloid plaques in the brain–10 to 15 years before cognitive symptoms such as confusion and memory loss begin.

Interventions that can slow or halt the formation of these plaques could prevent the chain reaction that leads to more devastating symptoms down the line, Tanzi said. The turning point seems to be when the brain accumulates enough plaques and tangles to prompt the microglia—the brain’s immune cells—to launch an all-out inflammatory attack on both harmful and healthy cells.

“Neuroinflammation at that stage kills at least 10 times more neurons than plaques and tangles, but it’s the plaques and tangles that kill enough neurons early on to trigger the immune system,” Tanzi said.

“I like to say that the plaques are like the match, the tangles are like the brush, but it’s the neuroinflammation that is the forest fire.”

By the time the patient has reached this stage it is likely too late to reverse course. This may be why so many clinical trials for drugs to treat Alzheimer’s patients have failed, Tanzi said.

“We’re taking patients where there is a forest fire blazing and thinking we can just blow out the match, and then we wonder why the trial doesn’t work.”

What’s Next

Tanzi and his colleagues are looking to identify new drugs, repurposed drugs or natural products that might be able to prevent the brain’s microglial cells from reaching that inflammatory tipping point. That point could vary from individual to individual depending on genetics, family history and lifestyle factors.

“We all have our own threshold of when we’re going to trigger neuroinflammation in response to X number of plaques and tangles,” he said.

“In the future we’ll be able to modulate that number through lifestyle modifications and early prevention and not get to that point. Because that is when the brain goes down the slippery slope. “


About the Mass General Research Institute
Research at Massachusetts General Hospital is interwoven through more than 30 different departments, centers and institutes. Our research includes fundamental, lab-based science; clinical trials to test new drugs, devices and diagnostic tools; and community and population-based research to improve health outcomes across populations and eliminate disparities in care.
Support our Research

No tags.

Related Post

  • To Mars and Beyond: Exploring Innovative Solutions to the Challenges of Space Travel

    By mghresearch | 1 comment

    If you could only bring two shoeboxes worth of medical supplies—from first aid kits to surgical tools— with you on a three-year space mission, what would you bring?

  • Antibiotic pills

    Are You Actually Allergic to Penicillin? Researchers Find New Methods to Confirm Antibiotic Allergies

    By mghresearch | 0 comment

    Mass General researchers are working to increase the safe use of penicillins in patients who have a recorded penicillin allergy but are not actually allergic.

  • Re-Thinking Mental Health Treatment: World Health Day 2017

    By mghresearch | 0 comment

    Did you know that more than 300 million people worldwide live with depression? That number has increased 18% between 2005 and 2015, according to the World Health Organization (WHO). With such staggering numbers, it’s no surprise that WHO has chosen depression as its theme for this year’s World Health Day, which is celebrated today, April 7th.

  • New Study Finds Low-Dose Aspirin May Lower Risk of Cancer Death

    By mghresearch | 1 comment

    A new study from Massachusetts General Hospital reports that long-term regular aspirin was associated with a lower risk of dying from various types of cancers.

  • Mass General Stands Up for Science

    By mghresearch | 0 comment

    The Boston March for Science will celebrate the discovery, understanding and sharing of scientific knowledge. Several groups from Massachusetts General Hospital are working together to organize and ensure a strong presence to reaffirm the message about the essential role that science – biomedical research, in particular – plays in improving life and health.

  • Adhering to Treatment During Adolescence Keeps HIV-Positive Youth on a Healthier Track

    By mghresearch | 0 comment

    Individuals born with HIV are more likely to have difficulty managing their treatment as teens and young adults than they did as children.

  • Celebrating the Role of Women in Science and Much More

    By mghresearch | 2 comments

    Interested in the newest research studies and hot topics? Check out the latest issues of “From the Lab Bench”, a monthly newsletter from the Office of the Scientific Director at the Mass General Research Institute, and “Research Roundup”, our monthly recap of the latest biomedical research news.

  • Research Rumble Recap and the Art of Effective Science Communication

    By mghresearch | 1 comment

    Last night five researchers from Massachusetts General Hospital and Brigham and Women’s Hospital showed off their science communication skills in a Research Rumble at the Cambridge Public Library as part of Cambridge Science Festival. Co-DirectorRead more

2 comments

  • Rudolf Fluckiger Reply October 10, 2019 at 10:29 am

    I observed that feeding the antioxidants pyrroloquinoline quinone (PQQ) and N-acetylcysteine (NAC) to a sunsetting dog, a model for human pre-Alzheimer’s disease markedly reduced the rate of progression of symptoms. We postulate that PQQ/NAC therapy that works in other conditions by creating an oxygen radical-free state that prevents the activation of Transient Potential Receptor (TRP) ion channels would also delay and or reverse AD symptoms in humans. In man the effective dosages are take twice daily the antioxidants pyrroloquinoline quinone (PQQ, 10 mg) and N-acetylcysteine (NAC, 600 mg). With modest funding we would carry out a pilot study to show that what we observed in an animal also works in humans. Lung cancer patients should not try this because antioxidants activate a gene promoting metastasis.

  • alzheimergadfly Reply October 11, 2019 at 10:33 am

    Tanzi in 2015 defended the amyloid hypothesis despite negative trials, basically blaming the trials: https://www.mdmag.com/medical-news/qanda-with-rudolph-tanzi-from-massachusetts-general-finding-therapies-for-alzheimers-disease-no-easy-task

    Interesting that he’s flexible enough to change his mind.

Leave a Comment

Cancel reply

Your email address will not be published. Required fields are marked *

  • About
  • About Us
  • Brain Research
  • Cancer
  • Communicating Science
  • Contenido en español
  • COVID-19
  • Events
  • Heart
  • History
  • Home (OLD)
    • Disclaimer
    • Home
  • Just kidding!
  • MGH Chief Academic Officer Job Description
  • MGRI Image Awards
  • MGRI Image Awards
  • MGRI Science Communications Intern
  • Research
  • Research News Funding Opportunities
  • Research News: Announcements & Events
  • Science Slam Tips and Tricks
  • Subscribe
Bench Press